The medical sector, buried under slumping drugmakers, still has a few big-capitalization stocks that have been shining.
Biotechs are down more than 20% this year, while ethical-drug makers are off more than 15% and generic-drug companies nearly 30%. Worries over pricing power have contributed to a bad sentiment for pharmaceuticals.